Analyst Reco. SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.82 ^USD	+18.18%		+26.39%	-18.39%

Apr. 09	SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases	CI
Mar. 28	SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ladenburg Thalmann Cuts SCYNEXIS Price Target to $7.50 From $15, Maintains Buy Rating	23-09-25	MT
Guggenheim Adjusts Price Target on SCYNEXIS to $9 From $8, Maintains Buy Rating	23-04-03	MT
Guggenheim Initiates SCYNEXIS at Buy With $8 Price Target	23-03-01	MT
Brookline Capital Assumes SCYNEXIS at Buy With $8 Price Target	22-10-21	MT
HC Wainwright Adjusts Price Target on SCYNEXIS to $8 From $14, Reiterates Buy Rating	22-05-13	MT
HC Wainwright Adjusts Price Target on SCYNEXIS to $14 From $20, Reiterates Buy Rating	22-03-31	MT
Maxim Group Adjusts SCYNEXIS Price Target to $11 From $16, Maintains Buy Rating	22-02-02	MT
SCYNEXIS : Aegis Capital Adjusts Price Target on SCYNEXIS to $35 From $40, Reiterates Buy Rating	21-06-07	MT
SCYNEXIS : Guggenheim Starts SCYNEXIS at Buy With $25 Price Target	21-01-22	MT
SCYNEXIS : Cantor Fitzgerald Starts SCYNEXIS at Overweight With $30 Price Target	21-01-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer